Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
CELC — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

25.22

Margin Of Safety %

Put/Call OI Ratio

0.29

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

3.44

Price

106.11

Target Price

128.6

Analyst Recom

1.18

Performance Q

3.32

Upside

-225.1%

Beta

0.42

Ticker: CELC



20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-02-27CELC111.770.130.0616580
2026-03-02CELC108.420.130.1416615
2026-03-03CELC107.340.130.4025177
2026-03-04CELC112.190.160.0228745
2026-03-05CELC115.320.160.8329015
2026-03-06CELC115.180.250.9935004
2026-03-09CELC114.450.250.0835778
2026-03-10CELC117.220.250.4835749
2026-03-11CELC115.810.250.9235683
2026-03-12CELC110.80.250.3135698
2026-03-13CELC110.770.250.3035698
2026-03-17CELC113.980.270.1335733
2026-03-18CELC112.450.270.0435749
2026-03-19CELC112.950.270.3835759
2026-03-20CELC106.120.270.1335759
2026-03-23CELC106.690.300.5329529
2026-03-24CELC101.910.300.0529624
2026-03-25CELC110.520.300.1629702
2026-03-26CELC115.060.290.5330471
2026-03-27CELC106.160.290.3830634
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1



20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-02-27CELC111.66-34.7- -3.67
2026-03-02CELC108.36-34.7- -3.67
2026-03-03CELC107.24-34.7- -3.67
2026-03-04CELC112.21-34.7- -3.67
2026-03-05CELC115.26-34.7- -3.67
2026-03-06CELC115.00-34.7- -3.67
2026-03-09CELC113.59-34.7- -3.67
2026-03-10CELC117.20-34.7- -3.67
2026-03-11CELC115.68-34.7- -3.67
2026-03-12CELC110.77-34.7- -3.67
2026-03-13CELC114.23-34.7- -3.67
2026-03-17CELC114.12-34.7- -3.67
2026-03-18CELC112.48-34.7- -3.67
2026-03-19CELC112.91-34.7- -3.67
2026-03-20CELC106.05-34.7- -3.67
2026-03-23CELC106.85-34.7- -3.67
2026-03-24CELC101.97-34.7- -3.67
2026-03-25CELC110.32-34.7- -3.67
2026-03-26CELC114.83-34.7- -3.67
2026-03-27CELC106.11-38.9- -4.52
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1



20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-02-27CELC1.2811.5426.85
2026-03-02CELC1.2811.6726.85
2026-03-03CELC1.2811.6726.85
2026-03-04CELC1.2811.6726.85
2026-03-05CELC1.2811.6726.85
2026-03-06CELC1.2811.6726.85
2026-03-09CELC1.2811.7226.85
2026-03-10CELC1.2811.7226.85
2026-03-11CELC-0.4311.7225.16
2026-03-12CELC-0.4311.7225.16
2026-03-13CELC-0.4311.7225.16
2026-03-17CELC-0.437.9525.16
2026-03-18CELC-0.437.9525.16
2026-03-19CELC-0.437.9525.16
2026-03-20CELC-0.437.9525.16
2026-03-23CELC-0.437.9525.16
2026-03-24CELC-0.437.9525.16
2026-03-25CELC-0.437.9525.22
2026-03-26CELC-0.437.9525.22
2026-03-27CELC-0.437.9525.22
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

-1.13

Avg. EPS Est. Next Quarter

-1.23

Insider Transactions

-0.43

Institutional Transactions

7.95

Beta

0.42

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

6

Growth Score

22

Sentiment Score

82

Actual DrawDown %

11.8

Max Drawdown 5-Year %

-82.7

Target Price

128.6

P/E

Forward P/E

PEG

P/S

P/B

50.87

P/Free Cash Flow

EPS

-3.79

Average EPS Est. Cur. Y​

-4.52

EPS Next Y. (Est.)

-1.08

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.48

Return on Equity vs Sector %

-166.5

Return on Equity vs Industry %

-150.2

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

-0.24

EBIT Estimation

◆ CELC Healthcare
$106.02
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
6/20
Pullback
13/25
Volume
3/15
Valuation
6/20
TP/AR
4/10
Options
8/10
RSI
45.5
Range 1M
40.2%
🚀
Momentum Growth
Ride accelerating trends
N/A
37 /100
WEAK
Momentum
7/25
Growth
11/30
Estimates
2/20
Inst/Vol
9/15
Options
8/10
EPS Yr
-3.2%
EPS NY
96.1%
52W%
89%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟡 HOLD +21.3% upside
Quality
2/30
Valuation
6/30
Growth
9/25
Stability
5/10
LT Trend
0/5
Upside
+21.3%
Quality
6
Click a card to see score breakdown Full Analysis →
Celcuity Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 155
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota.
CELC

Latest News

—
Caricamento notizie per CELC…
stock quote shares CELC – Celcuity Inc. Stock Price stock today
news today CELC – Celcuity Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CELC – Celcuity Inc. yahoo finance google finance
stock history CELC – Celcuity Inc. invest stock market
stock prices CELC premarket after hours
ticker CELC fair value insiders trading